{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:27:32Z","timestamp":1793824052678,"version":"4.6.1"},"reference-count":11,"publisher":"Elsevier BV","issue":"44","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Case Reports"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.jaccas.2026.108978","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:42:24Z","timestamp":1790714544000},"page":"108978","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating Hemodynamic Monitoring and Metabolic Therapy in Heart Failure"],"prefix":"10.1016","volume":"31","author":[{"given":"Candice","family":"Falls","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"44","key":"10.1016\/j.jaccas.2026.108978_bib1","article-title":"Glucagon-like peptide-1 agonist effects on weight loss and heart failure hemodynamics","volume":"31","author":"Alvarado","year":"2026","journal-title":"JACC Case Rep"},{"issue":"9","key":"10.1016\/j.jaccas.2026.108978_bib2","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.3390\/s24092922","article-title":"MEMS technology in cardiology: advancements and applications in heart failure management focusing on the CardioMEMS device","volume":"24","author":"Ciotola","year":"2024","journal-title":"Sensors"},{"issue":"1","key":"10.1016\/j.jaccas.2026.108978_bib3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cardfail.2010.08.002","article-title":"CHAMPION trial rationale and design: the long-term safety and clinical efficacy of a wireless pulmonary artery pressure monitoring system","volume":"17","author":"Adamson","year":"2011","journal-title":"J Card Fail"},{"issue":"9","key":"10.1016\/j.jaccas.2026.108978_bib4","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/s41591-023-02526-x","article-title":"Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial","volume":"29","author":"Borlaug","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jaccas.2026.108978_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.medcle.2025.106951","article-title":"GLP-1 receptor agonists in obesity treatment: effects on cardiometabolic variables and cardiovascular disease","volume":"165","author":"Sard\u00e0","year":"2025","journal-title":"Medicina Cl\u00ednica (English Edition)"},{"issue":"5","key":"10.1016\/j.jaccas.2026.108978_bib6","first-page":"556","article-title":"An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: a drug repositioning","volume":"23","author":"Rameshrad","year":"2020","journal-title":"Iran J Basic Med Sci"},{"issue":"1","key":"10.1016\/j.jaccas.2026.108978_bib7","first-page":"004","article-title":"Exenatide effects on cardiometabolic risk and weight in adolescents with morbid obesity and type 2 diabetes mellitus: two case reports","volume":"1","author":"Censani","year":"2015","journal-title":"J Obes Weight Loss Medicat"},{"issue":"12","key":"10.1016\/j.jaccas.2026.108978_bib8","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jaccas.2026.108978_bib9","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.jaccas.2026.108978_bib10","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol Metab"},{"issue":"7","key":"10.1016\/j.jaccas.2026.108978_bib11","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cardfail.2023.03.017","article-title":"Increased risk of heart failure hospitalization with GLP-1 receptor agonists in patients with reduced ejection fraction: a meta-analysis of the EXSCEL and FIGHT trials","volume":"29","author":"Neves","year":"2023","journal-title":"J Card Fail"}],"container-title":["JACC: Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266608492602139X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266608492602139X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:43:15Z","timestamp":1793821395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266608492602139X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":11,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S266608492602139X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccas.2026.108978","relation":{},"ISSN":["2666-0849"],"issn-type":[{"value":"2666-0849","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating Hemodynamic Monitoring and Metabolic Therapy in Heart Failure","name":"articletitle","label":"Article Title"},{"value":"JACC: Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccas.2026.108978","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccas.2026.110528","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"108978"}}